Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Current Leases: 2022-2025

Historic Current Leases for Dianthus Therapeutics (DNTH) over the last 3 years, with Sep 2025 value amounting to $217,000.

  • Dianthus Therapeutics' Current Leases fell 30.23% to $217,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $217,000, marking a year-over-year decrease of 30.23%. This contributed to the annual value of $320,000 for FY2024, which is 23.26% down from last year.
  • As of Q3 2025, Dianthus Therapeutics' Current Leases stood at $217,000, which was up 2.84% from $211,000 recorded in Q2 2025.
  • Over the past 5 years, Dianthus Therapeutics' Current Leases peaked at $3.6 million during Q3 2022, and registered a low of $211,000 during Q2 2025.
  • Over the past 3 years, Dianthus Therapeutics' median Current Leases value was $320,000 (recorded in 2024), while the average stood at $321,333.
  • Over the last 5 years, Dianthus Therapeutics' Current Leases had its largest YoY gain of 19.14% in 2023, and its largest YoY loss of 88.59% in 2023.
  • Over the past 4 years, Dianthus Therapeutics' Current Leases (Quarterly) stood at $350,000 in 2022, then increased by 19.14% to $417,000 in 2023, then dropped by 23.26% to $320,000 in 2024, then plummeted by 30.23% to $217,000 in 2025.
  • Its Current Leases stands at $217,000 for Q3 2025, versus $211,000 for Q2 2025 and $226,000 for Q1 2025.